<DOC>
	<DOC>NCT00809510</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.</brief_summary>
	<brief_title>A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>The subject was randomized into Study M06876 and completed the study. The subject must remain on the same dose of AChEI that was used during the M06876 study. The subject is in general good health, as judged by the investigator The subject is currently, or plans to participate in another experimental study during the course of this trial. The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>